Literature DB >> 18077719

Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Mikio Yoshioka1, Michelle M Crum, Jeffery T Sample.   

Abstract

Epstein-Barr virus (EBV) latent infection, and its associated oncogenic potential, is dependent on genome maintenance functions of EBV nuclear antigen 1 (EBNA-1), one of six EBNAs expressed from a common promoter (Wp and then Cp) upon infection of naive B cells. Subsequent host-mediated silencing, however, necessitates the expression of EBNA-1 from the EBNA-1-specific promoter Qp to ensure against genome loss during cell division, including EBV-associated malignancy. Here we addressed the mechanism by which EBNA-1 represses Qp through binding downstream of the transcription start site and the role of this autoregulatory function in EBV latency. Our results revealed that EBNA-1 does not inhibit transcription from Qp, as previously predicted, but acts post- or cotranscriptionally to block the processing of primary transcripts. This does not, however, require the RGG motifs responsible for strong but nonspecific RNA binding by EBNA-1. Within isogenic B-cell lines using either Cp/Wp or Qp, EBNA-1 occupancy of Qp is equivalent, suggesting that autoregulation occurs, albeit to different degrees, during full and restricted EBV latency programs. Finally, in cell lines using Cp or Wp for EBNA expression, unprocessed transcripts from Qp are detectable in the absence of corresponding mRNAs, providing further evidence that this novel mechanism of EBNA-1 action functions during latency. This posttranscriptional mechanism of regulation would provide an efficient means to monitor and regulate EBNA-1 expression from Qp, ensuring levels adequate for genome maintenance but, perhaps more importantly, below an immunogenic threshold above which latently infected cells may be at risk for elimination by EBNA-1-specific cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077719      PMCID: PMC2258721          DOI: 10.1128/JVI.02142-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

Authors:  Yili Yin; Bénédicte Manoury; Robin Fåhraeus
Journal:  Science       Date:  2003-09-05       Impact factor: 47.728

2.  The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element.

Authors:  C Nonkwelo; I K Ruf; J Sample
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

4.  CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.

Authors:  K D Robertson; A Manns; L J Swinnen; J C Zong; M L Gulley; R F Ambinder
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

5.  Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus.

Authors:  A Schepers; M Ritzi; K Bousset; E Kremmer; J L Yates; J Harwood; J F Diffley; W Hammerschmidt
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

6.  Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus.

Authors:  B Chaudhuri; H Xu; I Todorov; A Dutta; J L Yates
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

7.  Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.

Authors:  B C Schaefer; E Paulson; J L Strominger; S H Speck
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

8.  Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication.

Authors:  Zhong Deng; Larissa Lezina; Chi-Ju Chen; Svetlana Shtivelband; Wingkan So; Paul M Lieberman
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

9.  Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.

Authors:  Giovanna Cutrona; Elisabetta M Carpaneto; Anna Ponzanelli; Massimo Ulivi; Enrico Millo; Sonia Scarfì; Silvio Roncella; Umberto Benatti; Lidia C Boffa; Manlio Ferrarini
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

10.  Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.

Authors:  Gemma Kelly; Andrew Bell; Alan Rickinson
Journal:  Nat Med       Date:  2002-09-03       Impact factor: 53.440

View more
  17 in total

1.  Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.

Authors:  Italo Tempera; Alessandra De Leo; Andrew V Kossenkov; Matteo Cesaroni; Hui Song; Noor Dawany; Louise Showe; Fang Lu; Priyankara Wikramasinghe; Paul M Lieberman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency.

Authors:  David J Hughes; Carol A Dickerson; Marie S Shaner; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

3.  Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.

Authors:  Horng-Shen Chen; Kayla A Martin; Fang Lu; Lena N Lupey; Joshua M Mueller; Paul M Lieberman; Italo Tempera
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

4.  Epstein-Barr virus nuclear antigen 1 replication and segregation functions in nasopharyngeal carcinoma cell lines.

Authors:  Nirojini Sivachandran; Natalia N Thawe; Lori Frappier
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

5.  Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1.

Authors:  Scott Thompson; Troy Messick; David C Schultz; Melvin Reichman; Paul M Lieberman
Journal:  J Biomol Screen       Date:  2010-10

6.  CTCF prevents the epigenetic drift of EBV latency promoter Qp.

Authors:  Italo Tempera; Andreas Wiedmer; Jayaraju Dheekollu; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

7.  Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels.

Authors:  An T Phan; Samantha G Fernandez; Jessica J Somberg; Kristin M Keck; Jj L Miranda
Journal:  Biochem Biophys Res Commun       Date:  2016-04-16       Impact factor: 3.575

8.  Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes.

Authors:  Lindsay R Dresang; David T Vereide; Bill Sugden
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

Review 9.  Control of Viral Latency by Episome Maintenance Proteins.

Authors:  Alessandra De Leo; Abram Calderon; Paul M Lieberman
Journal:  Trends Microbiol       Date:  2019-10-14       Impact factor: 17.079

10.  EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication.

Authors:  Feroz Sarkari; Teresa Sanchez-Alcaraz; Shan Wang; Melissa N Holowaty; Yi Sheng; Lori Frappier
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.